-
Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer
04 Feb 2025 22:22 GMT
… limited-stage small cell lung cancer. If approved, these … with chemotherapy (carboplatin and paclitaxel) followed by Imfinzi … portfolio includes leading lung cancer medicines and the … improvements for people with lung cancer, including and beyond treatment …
-
EU approves endometrial, lung cancer drugs from GSK and J&J
21 Jan 2025 14:22 GMT
… (dostarlimab) given with carboplatin and paclitaxel chemotherapy achieved a 31% reduction … treatment for this type of lung cancer, and will be pivotal in …
-
Human medicines European public assessment report (EPAR): Abraxane, paclitaxel, Date of authorisation: 11/01/2008, Revision: 31, Status: Authorised
30 Jan 2025 17:24 GMT
… more effective than conventional paclitaxel-containing medicines. Overall, … the women receiving conventional paclitaxel-containing medicines (37 … effective than conventional paclitaxel-containing medicines in … In non-small cell lung cancer, 33% of patients …
-
Simultaneous Anti-Tuberculosis and Anti-Tumor Treatment with Immune Checkpoint Inhibitors for Co-Existent Pulmonary Tuberculosis and Advanced Lung Cancer
06 Jan 2025 10:41 GMT
… definitely answer whether lung cancer complicated by Mycobacterium … nodes, indicating possible lung cancer with metastasis. Additionally … drugs (carboplatin and paclitaxel). Typically, immune- … -existent tuberculosis and lung cancer. Lung Cancer. 2018;122:83 …
-
Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
18 Dec 2024 12:41 GMT
… mutant advanced non-small cell lung cancer (NSCLC). No dose-limiting … G12C mutant non-small cell lung cancer.”
RAMP 203 Clinical Update … G12C mutant non-small cell lung cancer (NSCLC) who have not … with gemcitabine/nab-paclitaxel in patients with front-line …
-
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
07 Dec 2024 12:42 GMT
… metastatic non-small cell lung cancer (NSCLC) not … Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer … , accounting for approximately 85% of all lung cancer … NSCLC, and with paclitaxel and carboplatin for squamous …
-
AstraZeneca's Imfinzi receives US FDA approval to treat patients with limited─stage small cell lung cancer
06 Dec 2024 04:06 GMT
… extensive-stage small cell lung cancer, underscoring our commitment … chemotherapy (carboplatin and paclitaxel) followed by Imfinzi … portfolio includes leading lung cancer medicines and the … improvements for people with lung cancer, including and beyond …
-
The Targeted Pulse: The FDA Grants MB-105 ODD, and AI Helps Distinguish HER2 0 From 1+ in Breast Cancer
09 Feb 2025 14:16 GMT
… with non–small cell lung cancer (NSCLC) harboring EGFR … the full article here.
Paclitaxel Showdown: Oral Bests IV …
The oral solution of paclitaxel (Liporaxel) outperformed the intravenous … The oral solution of paclitaxel demonstrated a favorable safety …
-
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
05 Dec 2024 12:23 GMT
… Notes
Small cell lung cancer
Lung cancer is the leading … chemotherapy (carboplatin and paclitaxel) followed by IMFINZI … for people with lung cancer, including and beyond … lung-cancer-101/types-of-lung-cancer.
American Cancer Society. Small cell lung cancer …
-
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations
03 Dec 2024 11:55 GMT
… and Taiwan).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … and either paclitaxel or paclitaxel protein-bound, … and either paclitaxel or paclitaxel protein-bound …
About
© 1995-2025